Life Sciences

  • May 15, 2026

    Fed. Circ. Drops A Theme Song, Talks Guest Judges

    The Federal Circuit's full lineup came together Friday to provide practitioners with insight about their experience sitting on other courts, in a conference where the chief judge dropped the court's first (and only) single.

  • May 15, 2026

    Med Device Groups 'Overshot' In Fair Use Args, Judge Says

    A judge on a D.C. Circuit panel said a set of industry groups covering the advanced medical device industry might have "overshot" in a challenge to a Library of Congress exemption that said use of copyrighted software for the purpose of repairing those devices fell under fair use, since the groups tried to lump the software that merely operates the machines into the case.

  • May 15, 2026

    Pharmacies Stuck With CVS Arbitration Mandate At 9th Circ.

    A Ninth Circuit panel refused Friday to let four independent pharmacies avoid arbitrating their antitrust claims that CVS exploited a Medicare loophole to charge them exorbitant fees, standing by a district court's conclusion that just because parts of the arbitration agreement were unconscionable doesn't negate the entire thing.

  • May 15, 2026

    Edwards Investors Sue In Chancery Over $16.4B Stock Drop

    A stockholder has sued Edwards Lifesciences Corp.'s current and former leaders in Delaware Chancery Court, claiming they misled investors about growth prospects for the medical device company's key artificial heart valve business before a July 2024 disclosure wiped out more than $16.4 billion in shareholder value.

  • May 15, 2026

    Texas Hospital Creates 'De-Transition Clinic' After Settlement

    The Texas attorney general announced a settlement with Texas Children's Hospital that will see the creation of a detransition clinic, saying Friday that the hospital will pay $10 million for billing Texas Medicaid for "illegal 'gender-transition' interventions."

  • May 15, 2026

    4th Circ. Hands Express Scripts Jury Trial In W.Va. Opioid Suit

    The Fourth Circuit on Friday issued a writ of mandamus backing Express Scripts Inc.'s right to a jury trial in litigation over the pharmacy benefit manager's alleged role in contributing to the opioid crisis in West Virginia.

  • May 15, 2026

    Insurer Owes No Coverage In Ill. Genetic Testing Fraud Suit

    An insurer does not have to defend an embryo storage lab against a proposed class action alleging it used deceptive marketing to sell genetic testing services to IVF patients, because misleading promotion doesn't fall under the lab's coverage, an Illinois federal judge has ruled.

  • May 15, 2026

    $19.2M Joint Juice Deal Ends Calif. False Ad Suit

    A California federal judge has given final approval to a nearly $19.2 million settlement to end more than a decade of litigation alleging that the makers of Joint Juice misled consumers about its health benefits.

  • May 15, 2026

    Marketer Says It Was Pawn In Med Supplier's Crypto Pivot

    A Massachusetts marketing firm says a medical supply company used it to broker a $50 million deal with another supplier, touted the arrangement to investors, then abruptly turned itself into a cryptocurrency business, stiffing the plaintiff out of anticipated commissions.

  • May 14, 2026

    Squires Lays Out Principles For Patent Review Discretion

    U.S. Patent and Trademark Office Director John A. Squires issued a precedential decision Thursday outlining the principles underlying his discretion in instituting America Invents Act reviews, emphasizing that Congress intended such reviews to be an alternative to costly and lengthy litigation.

  • May 14, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Members of Congress approved language in a funding bill that would block the rescheduling of marijuana, Colorado lawmakers gave final approval to a bill to fund research into the psychedelic ibogaine and authorize the establishment of licensed treatment centers, and Rhode Island lawmakers introduced legislation to eliminate geographic criteria from the state's cannabis social equity program.

  • May 14, 2026

    NC Republicans Want Fetal Personhood Question On '26 Ballot

    Two Republicans in the North Carolina House who have a history of advancing so-called fetal personhood bills have made another attempt to put a constitutional amendment to voters in November to decide if life begins at fertilization.

  • May 14, 2026

    Takeda To Pay $13.6M Over Antidepressant Drug Kickbacks

    Takeda Pharmaceuticals will pay $13.6 million to end allegations that it caused false Medicaid claims by providing kickbacks to healthcare providers to push prescriptions of its antidepressant drug Trintellix, the U.S. Department of Justice announced Thursday.

  • May 14, 2026

    Human Reproduction Proves Talc Can Reach Ovaries, Jury Told

    A medical oncologist on Thursday told a Los Angeles bellwether jury considering claims that Johnson & Johnson's talc products caused three women's deadly ovarian cancer that the female reproductive system is an "open" system where talc can migrate to the ovaries, and that "we wouldn't exist" if that was not the case.

  • May 14, 2026

    Squires Walks Back 5 More IPR Grants Over Inconsistent Args

    U.S. Patent and Trademark Office Director John Squires has reversed earlier decisions granting five petitions for patent review, citing what he called the challengers' inconsistent positions in parallel proceedings and explaining that four petitions he denied in previous bulk orders were also rejected for the same reasons. 

  • May 14, 2026

    House Passes Bill To Narrow Biofuel Blending Exemption

    The U.S. House of Representatives has passed a bill that would lift summertime restrictions on the sale of higher-ethanol fuel and tighten requirements for a biofuel blending exemption for small refineries.

  • May 14, 2026

    Med Device Co.'s CEO Touted Growth, Netted $39M, Suit Says

    Medical device maker Integer Holdings Corp.'s former CEO overstated growth prospects of a manufacturing program for the company's electrophysiology business, inflating the firm's stock price and allowing him to reap a nearly $39 million "windfall net profit," according to an investor's derivative lawsuit in Texas federal court.

  • May 14, 2026

    Albertsons Not Covered In Opioid Litigation, Del. Judge Says

    Albertsons isn't entitled to defense or indemnity for more than 100 suits accusing the pharmacy and grocery chain of fueling the opioid epidemic, a Delaware state court ruled, tracking the state high court's rulings in nearly identical disputes involving Rite Aid and CVS.

  • May 14, 2026

    Insider Trading Case Shows BigLaw Associate Vetting Gaps

    A BigLaw attorney who was able to move through three major firms while allegedly orchestrating a massive insider trading scheme may have been aided by relatively loose hiring practices for associates that firms may consider strengthening moving forward, recruiting experts told Law360.

  • May 14, 2026

    Fortive, Subsidiary Seek Early Win In Wrongful Firing Suit

    Technology company Fortive and a medical equipment subsidiary asked a Colorado federal judge for an early win in a former regional sales director's lawsuit alleging she was fired for raising concerns about compliance with anti-kickback rules, contending the subsidiary terminated her due to a restructuring and that Fortive wasn't her employer.

  • May 14, 2026

    High Court Maintains Abortion Pill Access Amid Circuit Appeal

    The U.S. Supreme Court on Thursday extended a stay preserving telehealth access to the abortion medication mifepristone while the Fifth Circuit weighs a challenge to the mail-order distribution of the pill.

  • May 14, 2026

    Takeda Cashed In From Delay Of Generic IBS Drug, Jury Told

    Drug buyers urged a Massachusetts federal jury on Thursday to find that Takeda Pharmaceuticals conspired with another drugmaker to keep a generic version of anticonstipation drug Amitiza off the market in order to boost its own profits. 

  • May 14, 2026

    BeiGene Must Face AbbVie's Chemical Trade Secret Claims

    An Illinois federal judge has denied oncological research company BeiGene's request to escape claims from AbbVie Inc. that it poached a retired scientist to obtain trade secrets related to a certain chemical compound, saying BeiGene failed to back up its arguments.

  • May 14, 2026

    Ex-Investor Seeks Records On $8.9B Thermo Fisher Payout

    A former equity holder of Clario Holdings Inc., a clinical-trial technology company, has sued in the Delaware Chancery Court, seeking records she says she needs to understand how her payout was calculated after Thermo Fisher Scientific Inc.'s $8.875 billion cash acquisition of Clario.

  • May 14, 2026

    Ga. Panel Quiet On Fate Of $20M Bard Cancer Verdict

    A Georgia appellate panel gave few indications Thursday of whether it would order a new trial in a former C.R. Bard worker's lawsuit alleging that exposure to ethylene oxide caused his cancer, weighing whether a mistrial on punitive damages necessitates scrapping a $20 million compensatory damages verdict.

Expert Analysis

  • NY's Growing Enviro Reg Framework Will Transform Projects

    Author Photo

    Three closely connected environmental rulemakings in New York state — concerning greenhouse gas reporting, remediation standards and amendments to the State Environmental Quality Review Act — have reached critical stages, and taken together, they will have major impacts on business operations, construction project timelines and transactional risk, say attorneys at Holland & Knight.

  • How 'Spillover' Effects Can Skew AI Securities Class Actions

    Author Photo

    Event study evidence is often central in securities litigation at class certification and beyond, but in an environment where earnings forecasts and statements can have spillover market implications, particularly when concerning artificial intelligence, the task of parsing out the price impact of news requires careful consideration, say Erik Johannesson, Olivia Wurgaft and Nguyet Nguyen at Brattle Group.

  • Previewing FDA National Priority Vouchers In Psychedelics EO

    Author Photo

    President Donald Trump's recent executive order on psychedelic drug access represents a watershed moment in federal drug policy, but its significance lies in two distinct regulatory pathways, the first being the Commissioner's National Priority Vouchers, which offer a significant opportunity to compress U.S. Food and Drug Administration review, say Kimberly Chew at Husch Blackwell and Odette Hauke at Odette Alina.

  • Series

    Playing Magic: The Gathering Makes Me A Better Lawyer

    Author Photo

    The competitive card game Magic: The Gathering offers me a training ground for the strategic thinking skills crucial to litigation, challenging me to adapt to oft-updated rules, analyze text as complicated as any statute and anticipate my opponent’s next moves, says Christopher Smith at Lash Goldberg.

  • Why Product-Based Public Nuisance Claims May Be Waning

    Author Photo

    The Maryland Supreme Court's recent decision in Express Scripts v. Anne Arundel County is the latest in a national trend of rulings rejecting product-based public nuisance claims — but other forms of government litigation against companies that allegedly increase the cost of public services are likely to continue, say attorneys at Simpson Thacher.

  • Improving Well-Being In Law, 10 Years After Landmark Study

    Author Photo

    An important 2016 study revealed significant substance abuse and mental health issues among lawyers, and while the findings helped normalize the conversation around these topics, a decade later, structural change is still needed, says Denise Robinson at PLI.

  • How To Gear Up For Trump's Pharma Tariffs

    Author Photo

    President Donald Trump's proclamation establishing tariffs on certain pharmaceutical products holds a few areas of ambiguity that companies should review and prepare for before the tariffs come into effect later this year, say attorneys at Arnold & Porter.

  • How The Coming Months Will Shape State Drug Price Boards

    Author Photo

    The future of state prescription drug affordability boards may be determined in the next few months, between an upcoming court decision in a challenge against state authority to set drug prices, and pending state decisions about whether to use federal Medicare maximum fair prices as reference, say Michael Kolber, Steven Chen and Kelechi Ezealaji at Manatt.

  • High Court 'Skinny Label' Case Will Matter To Tech Litigators

    Author Photo

    Hikma v. Amarin, set for oral argument in the U.S. Supreme Court on Wednesday, has potential to affect not just generic drug label-based evidence in patent cases, but also how technology inducement cases are presented and proven, says attorney Abdul Abdullahi.

  • How Food, Beverage Claims May Preview Cosmetic Litigation

    Author Photo

    Class action litigation targeting cosmetics and personal care products is accelerating, with a playbook that comes from the food and beverage industry — and the defenses that succeeded, and failed, in past class actions offer a critical road map for beauty and personal care brands, say attorneys at Crowell.

  • Court's HRSA Policy Reversal Leaves 340B Rules Murky

    Author Photo

    A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.